Complete remission of pulmonary metastases of bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab

American Journal of Case Reports

Volumn 13, Issue , 2012, Pages 1-2

  Barrascout, Eduardo ^a   Beuselinck, Benoit ^a   Ayllon, Jorge ^a   Bättig, Basil ^b   Moch, Holger ^c   Teghom, Corine ^a   Oudard, Stephane ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Onkologie Bellevue ^*  (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Bellini carcinoma; Bevacizumab; Complete response

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; LOW MOLECULAR WEIGHT HEPARIN; THYROID TRANSCRIPTION FACTOR 1;

ADULT; ARTICLE; BELLINI DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; FOLLOW UP; HEMATURIA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG EMBOLISM; LUNG METASTASIS; MAINTENANCE CHEMOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84856287073     PISSN: None     EISSN: 19415923     Source Type: Journal    
DOI: 10.12659/AJCR.882234     Document Type: Article

References (5)

1. Srigley JR, Delahunt B: Uncommon and recently described renal carcinomas. Mod Pathol, 2009; 22(Suppl.2): S2-23
2. Tokuda N, Naito S, Matsuzaki O et al: Japanese Society of Renal Cancer. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol, 2006; 176: 40-43
3. Oudard S, Banu E, Vieillefond A et al: Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro- Génitales) Study. J Urol, 2007; 177: 1698-702
4. Staehler M, Schöppler G, Haseke N et al: Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib. Clin Genitourin Cancer, 2009; 7: 58-61
5. Burger RA, Brady MF, Bookman MA et al: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol, 2010; 28: 18s(Suppl; abstr LBA1)